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Abstract
Background: Patient-Derived Tumour Xenografts (PDTXs) have emerged as the pre-clinical models that best
represent clinical tumour diversity and intra-tumour heterogeneity. The molecular characterization of PDTXs using
High-Throughput Sequencing (HTS) is essential; however, the presence of mouse stroma is challenging for HTS data
analysis. Indeed, the high homology between the two genomes results in a proportion of mouse reads being
mapped as human.
Results: In this study we generated Whole Exome Sequencing (WES), Reduced Representation Bisulfite Sequencing
(RRBS) and RNA sequencing (RNA-seq) data from samples with known mixtures of mouse and human DNA or RNA
and from a cohort of human breast cancers and their derived PDTXs. We show that using an In silico Combined
human-mouse Reference Genome (ICRG) for alignment discriminates between human and mouse reads with up to
99.9% accuracy and decreases the number of false positive somatic mutations caused by misalignment by >99.9%.
We also derived a model to estimate the human DNA content in independent PDTX samples. For RNA-seq and
RRBS data analysis, the use of the ICRG allows dissecting computationally the transcriptome and methylome of
human tumour cells and mouse stroma. In a direct comparison with previously reported approaches, our method
showed similar or higher accuracy while requiring significantly less computing time.
Conclusions: The computational pipeline we describe here is a valuable tool for the molecular analysis of PDTXs as
well as any other mixture of DNA or RNA species.
Keywords: In silico combined human-mouse reference genome, High throughput sequencing, Short-reads,
Alignment, ICRG, Mouse stroma, Patient-derived tumour xenografts
Background
Patient-Derived Tumour Xenografts (PDTXs) are
emerging as the pre-clinical models that best repre-
sent the diversity of clinical tumours and intra-
tumour heterogeneity [1–3]. PDTXs have been shown
to be robust models to study tumour progression and
evolution, test new cancer drugs and drug combina-
tions, and unravel drug resistance mechanisms, con-
tributing to the aim of reducing the high attrition
rate in cancer drug development [4–8].
In the era of cancer genomics and precision medicine, the
molecular analysis of PDTXs is a central component of
their characterization. High-Throughput Sequencing (HTS)
is used to profile these models at the genomic, epigenomic
and transciptomic levels. We and others have observed that
after implanting human cancer tissue fragments into
immuno-compromised mice, the human stroma is rapidly
lost and replaced by mouse stromal cells [2, 9, 10]. This re-
sults in an unknown proportion of mouse cells incorporated
into the xenograft. As a consequence, a proportion of the
sequencing reads obtained by HTS will be of mouse origin.
Given the high homology of human and mouse genomes,
mouse reads can be wrongly aligned to the human genome,
hampering downstream analyses and data interpretation.
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Previous studies have tried to address this issue.
Conway et al. developed Xenome, a tool able to clas-
sify sequencing reads belonging to two different spe-
cies; the output is a set of FastQ files that still need
to be aligned to the appropriate genome [11]. More
recently, Ahdesmäki and colleagues presented Dis-
ambiguate, that takes as input two bam files ob-
tained by aligning the same FastQ file to the two
relevant genomes and then classifies each read based
on the alignment scores [12]. Currently, this ap-
proach can be used only in combination with a spe-
cific set of aligners.
Here we present a computational approach to distin-
guish human and mouse reads in HTS data based on the
use of an In silico Combined human-mouse Reference
Genome (ICRG) in the alignment step. We demon-
strated the accuracy of the approach using control sam-
ples and a set of matched human breast cancers and
derived PDTXs. In a direct comparison with Disambigu-
ate and Xenome, our approach was quicker while show-
ing similar or higher accuracy.
Results
Optimizing sequence alignment using the ICRG
In PDTX samples, a proportion of HTS reads originated
from mouse DNA could have high enough homology to
be aligned to the HRG. We reasoned that using the
ICRG as the reference should allow the alignment soft-
ware to find, for those mouse DNA reads, a better align-
ment score on the mouse genome, since both genomes
are available simultaneously to the aligner software. This
could represent the basis to accurately distinguish hu-
man and mouse reads in HTS data originated from
PDTX models.
To test this hypothesis, we performed WES in a dilution
series containing known amounts of human and mouse
DNA (Table 1). Sequencing data were aligned to both the
HRG and the ICRG. In the 100% human DNA sample, a
statistically significant decrease in alignment efficiency
was observed when using the ICRG instead of the HRG
(average efficiency = 90.48% for the HRG and 90.28% for
the ICRG, paired t-test P = 0.009), however, the decrease
in performance was negligible (0.2%). Aligning the WES
data obtained by sequencing the 100% mouse DNA sam-
ples onto the HRG revealed that, on average, 6.9% of the
reads were misaligned. As we show below, these misa-
ligned reads are detrimental for downstream analyses. For
example, a graphical representation of this misaligned
mouse reads effect on a PTEN exon is shown in Fig. 1a.
Mouse reads are wrongly aligned to the human genome if
sequence similarity is high enough, but since identity is
not 100%, all the mismatched bases could be called as
false positive ‘somatic mutations’. In contrast, using the
ICRG avoids this artefact altogether (Fig. 1a).
To study systematically the effectiveness of using the
ICRG as a reference genome, we computed the percentage
of reads mapping to the human and mouse genomes. As
shown in Table 1, more than 99.9% of the reads from the
pure human DNA sample and from the pure mouse DNA
sample mapped to the correct genome. In diluted human-
mouse DNA samples, the percentage of reads mapped to
the correct genome did not match perfectly the percentage
of input human and mouse DNA. Nevertheless, there was
a non-linear relationship between the percentage of reads
mapped to the human genome and the fraction of human
DNA in the sample (Fig. 1b). We hypothesized this resulted
from the enrichment step during WES library preparation,
since the capture probes used have been designed for
Table 1 Alignment of WES data from the human-mouse DNA dilution series
% of
human
DNA
%of
mouse
DNA
Replicate Alignment efficiency
human genome %
Alignment efficiency
combined genome (%)
%of reads mapped on
the human genome
%of reads mapped on
the mouse genome
Estimated
human DNA
content
100 0 a 90.81 90.64 99.98 0.02 99.89
100 0 b 90.38 90.16 99.98 0.02 99.88
100 0 c 90.26 90.13 99.98 0.02 99.89
90 10 a 88.57 90.43 97.59 2.41 90.22
90 10 b 88.53 90.39 97.58 2.42 90.16
50 50 a 75.65 89.37 83.14 16.86 50.73
50 50 b 74.90 89.71 82.18 17.82 49.01
50 50 c 75.41 89.55 82.78 17.22 50.07
25 75 a 58.07 89.25 62.44 37.56 23.97
25 75 b 60.25 89.48 64.58 35.42 26.17
0 100 a 7.01 88.77 0.10 99.90 0.00
0 100 b 7.17 88.56 0.10 99.90 0.00
0 100 c 6.65 88.95 0.08 99.92 0.00
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human exons. A careful look at the data revealed that using
a generalised additive model was able to accurately estimate
the human DNA content (Table 1). This model was used to
estimate the mouse DNA content (as 100 - human DNA
content) in a set of matched samples (normal/tumour/
PDTX) for whichWES data was available (Additional file 1).
The model estimate of mouse DNA content for all primary
human samples was negligible while the estimate ranged
between 4.2 and 15.0% in PDTX samples (Fig. 1c).
Improvement of mutation calling in WES PDTX data using
the ICRG
The analysis of PDTX WES data aims at the identifica-
tion of somatic mutations. However, the presence of
misaligned mouse reads is likely to increase the false
positive mutation rate. Therefore, we quantified the
problem and verified whether the use of the ICRG for
sequence alignment could effectively overcome it.
For each pair of PDTX and its originating clinical
tumour, we identified the somatic mutations and quanti-
fied how many were present only in the tumour, only in
the PDTX or in both. The analysis was performed on
WES data aligned to either the HRG or the ICRG. Results,
reported in Fig. 2a, show that the number of tumour spe-
cific mutations identified across 10 PDTX-clinical tumour
pairs was not significantly affected by the reference gen-
ome used for alignment (average = 31.9 for the HRG and
32.5 for the ICRG, paired t-test P = 0.140). Similarly, no
significant difference was observed for the common muta-
tions (average = 113.1 for the HRG and 109.9 for the
ICRG, paired t-test P = 0.086). In contrast, the number of
PDTX specific mutations was high when the HRG was
a
b c
Fig. 1 Use of the ICRG in WES data. a IGV plot of PTEN exon 5 (WES data from 25% human/75% mouse DNA sample). Top panel: bam files after
alignment to the HRG. Bottom panel: bam files after alignment to the ICRG. Mismatching bases are highlighted using the corresponding colour code
(A = green, C = blue, G = orange, T = red). b Correlation plot between the percentage of reads mapped to the human genome and percentage of
human DNA content in the sample. The solid line shows the calibration curve fitted to the data using penalized regression splines and grey dashed
lines show the standard error. c Prediction of mouse DNA content in primary human and PDTX samples using the calibration curve in (b)
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used and decreased dramatically by using the ICRG in the
alignment step (average = 306.1 using HRG and 68.8 using
ICRG, paired t-test P = 0.004).
To quantify the percentage of PDTX specific muta-
tions caused by misalignment of mouse reads, we com-
puted their VAF in one of the 100% mouse samples
(replicate c in Table 1). As before, we repeated the ana-
lysis after alignment to the HRG or the ICRG (Fig. 2b).
Of the 3123 PDTX specific mutations identified in the
10 PDTX-clinical tumour pairs aligned to the HRG,
2496 (79.9%) were present in the 100% mouse sample
and are therefore false positives caused by the presence
of mouse reads. Strikingly, only 712 PDTX specific mu-
tations were identified in WES data aligned to the ICRG
and only two of them were caused by mouse reads mis-
alignment (Fig. 2b). In conclusion, the use of the ICRG
was effective in removing >99.9% of false positive muta-
tions caused by misaligned mouse reads.
The number of false positives caused by mouse reads
is mostly a result of the mouse DNA content and se-
quencing depth. We noticed that even a small content of
mouse DNA could generate a large number of false posi-
tive mutation calls. As an example, in Case_2_PDX1, se-
quenced with 69× coverage and with an estimated 7.2%
Case_1_PDTX1 Case_1_PDTX2 Case_1_PDTX3 Case_2_PDTX1 Case_4_PDTX1
Case_4_PDTX2 Case_4_PDTX3 Case_4_PDTX5 Case_5_PDTX2 Case_5_PDTX3
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Fig. 2 Impact of mouse reads on somatic mutation calling. a Bar plots showing numbers of somatic mutations identified in clinical tumours and
matched PDTXs after alignment against either the HRG or the ICRG. Within each pair of clinical tumour and PDTX (n = 10), mutations were classified as
‘tumour specific’ (i.e. present in the tumour but not in the matched PDTX), ‘PDTX specific’ (i.e. present in the PDTX but not in the originating clinical
tumour) and common (present in both tumour and PDTX). b Bar plots showing VAFs for all ‘PDTX specific’ mutations identified in the 10 pairs in (a) in
the 100% mouse sample. Left panel- data aligned to the HRG; Right panel- data aligned to the ICRG
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mouse DNA content (Fig. 1c) a total of 405 false positive
mutations specifically caused by misaligned mouse reads
were identified when data were aligned to the HRG.
Using the ICRG in the analysis of RRBS data
We next tested the usefulness of the ICRG in RRBS data
analysis. To this aim, we profiled a set of normal,
tumour and PDTX samples (Additional file 1). As shown
in Table 2, in clinical samples the alignment efficiency
was not affected by the reference genome used (average
efficiency = 72.2 for the HRG and 72.4 for the ICRG,
paired t-test P = 0.319). In contrast, the overall alignment
efficiency increased in PDTX samples when the ICRG
was used (average efficiency = 67.8 for the HRG and 72.7
for the ICRG, paired t-test P = 0.010). Such increase can
be explained by the fact that the aligner could map most
of the mouse reads present in the samples when the
ICRG was used. In clinical samples, >98.8% of the reads
were correctly mapped to the human genome (at least
99.9% in all but one). In contrast, in PDTXs, 2.6–23.1%
of the reads mapped to the mouse genome (Table 2).
The number of human CpGs having coverage higher
than 5 was slightly lower when using the ICRG, but the
magnitude of this effect was negligible. Indeed, we ob-
served an average 0.06% ± 0.01 reduction in the number
of CpGs in normal and tumour samples and 0.10% ±
0.04 in PDTX samples. CpG coverage was very similar
independently of the reference genome used for align-
ment (average correlation >0.999 for normal and tumour
samples as well as for PDTX samples) and similar results
were obtained looking at the percentage of methylation
in each human CpG (average correlation >0.999 for nor-
mal and tumour samples as well as for PDTX samples).
All together, these results suggest that the use of the
ICRG for sequence alignment accurately discriminates be-
tween human and mouse reads in RRBS data. Conse-
quently, this approach can enable the analysis of mouse
stroma specific methylation signals. Indeed, in three of the
PDTX samples, more than 2 × 10^5 mouse CpGs could be
queried, a reasonable number to derive an informative
methylation profile. As noted above, the number of mouse
CpGs available for analysis depends on both sequencing
coverage and percentage of mouse stroma in the sample.
Using the ICRG allows dissecting expression of mouse
stroma genes in PDTX-derived RNA-seq data
We tested the effect of using the ICRG in analysing
PDTX RNA-seq data. First we evaluated the impact of
the reference genome using the Human Reference RNA
(HRR) and Mouse Reference RNA (MRR) samples for
which RNA-seq data were obtained in triplicate (Table 3).
In HRR samples the alignment efficiency was basically
not affected by the reference genome used, although,
statistically, a significant increase was observed (average
efficiency = 79.05 for the HRG and 79.10 for the ICRG,
paired t-test P = 0.019). In addition, using the ICRG,
99.8% of the reads from the HRR samples aligned to the
human genome, and 98.9% of the reads from the MRR
samples aligned to the mouse genome (Table 3). This
reassured us that we could use the ICRG approach to
distinguish between mouse and human transcripts in
bulk RNA-seq data generated from PDTXs.
Table 2 Alignment of RRBS data and CpG quantification
Sampler HRG ICRG Common
human
CpGs (%)
Alignment
efficiency (%)
n. of
human
CpGsa
Alignment
efficiency (%)
Reads mapped to the
human genome (%)
Reads mapped to the
mouse genome (%)
n. of
human
CpGsa
n. of
moue
CpGsa
Case_1_Normal 72.2 2,317,726 72.2 99.9 0.1 2,315,989 102 99.9
Case_1_Tumuor 74.1 2,676,050 74.1 99.9 0.1 2,674,961 119 99.9
Case_1_PDTX3 71.5 3,560,299 73.8 96.8 3.2 3,556,996 223,997 99.9
Case_2_Normal 70.6 1,893,234 70.6 99.9 0.1 1,891,949 60 99.9
Case_2_Tumuor 71.2 2,071,412 72.1 98.8 1.2 2,070,098 452 99.9
Case_2_PDTX1 68.5 2,132,270 73.4 93.2 6.8 2,130,231 90,072 99.8
Case_3_PDTX2 67.4 2,620,064 70.8 95.2 4.8 2,617,504 99,418 99.8
Case_3_PDTX3 54.7 1,623,532 71.0 76.9 23.1 1,620,101 339,859 99.7
Case_4_PDTX1 73.1 2,812,733 75.0 97.4 2.6 2,811,314 47,455 99.9
Case_4_PDTX2 69.1 1,503,423 72.3 95.6 4.4 1,501,890 13,819 99.8
Case_4_PDTX3 71.1 1,468,861 74.0 96.1 3.9 1,467,659 24,082 99.9
Case_4_PDTX5 69.2 3,185,468 73.5 94.0 6.0 3,182,452 264,898 99.9
Case_5_Tumuor 72.8 3,004,752 72.8 99.9 0.1 3,003,290 87 99.9
Case_5_PDTX3 65.8 2,066,808 70.6 93.0 7.0 2,064,469 179,031 99.8
acoverage > 5
Callari et al. BMC Genomics  (2018) 19:19 Page 5 of 12
We observed that, in the MRR sample, an average of
5.2% of the reads mapped to the human genome if the
HRG was used as reference for alignment (Table 3). To
evaluate the impact of these reads on the quantification
of human transcripts, we computed the read counts for
all human genes in the HRR and MRR samples after
alignment against either the HRG or the ICRG respect-
ively. As shown in Fig. 3a-b, in the HRR samples, gene
expression quantification was not affected by the refer-
ence genome used. Indeed, the Pearson correlation be-
tween read counts in data aligned to the HRG and read
counts in data aligned to the ICRG was >0.999 for all
replicates. In the MRR samples, the bulk of human
genes already had read count 0 or close to 0 when using
the HRG for alignment (Fig. 3c). However, an average of
1565 genes (across the three MRR replicates) had read
counts higher than 100, but with the use of the ICRG
for alignment the number dropped to 25 genes (Fig. 3c-
d). Therefore, the presence of mouse reads could intro-
duce some bias in the quantification of a subset of
human genes and the use of the ICRG in the alignment
step drastically reduce this artefact.
We generated RNA-seq data for a set of matched hu-
man breast cancer samples and PDTXs (Additional file 1).
As expected, in primary human samples, the percentage
of reads mapped to the mouse genome was as low as
0.1%. In contrast, in the matched PDTX samples, between
3 and 27.6% of the RNA-seq reads were aligned to the
mouse genome (Fig. 3e). Consequently, the use of the
ICRG for alignment enables the in silico dissection of the
human and mouse transcriptomes, and hence the study of
gene expression signals from the human tumour cells and
the mouse microenvironment in PDTXs.
The number of mouse genes detected in the PDTX
samples depends on the amount of mouse stroma in the
sample as well as sequencing depth. In our cohort of
PDTXs (n = 15) sequenced to an average depth of 21
million reads per sample, 4275 mouse genes had a FPKM
>1 in at least 50% of the samples. Not surprisingly, fibro-
blast and extracellular matrix specific genes like Sparc,
Bgn, cathepsins and collagens were among the top 50
most expressed mouse genes (Additional file 2: Table S2).
Interestingly, in an unsupervised Principle Component
Analysis using mouse gene expression values, different
passages of the same PDTX model tended to cluster to-
gether, and apart from the other models [except for one
outlier sample: C3_PDTX3] (Fig. 3f).
Comparison with other methods
As a final step, we wanted to compare our approach
with previously described methods, in particular Disam-
biguate [12] and Xenome [11]. For this comparison, we
selected the 100% human DNA samples and 100%
mouse DNA samples WES data, as well as the HRR and
MRR RNA-seq data.
WES data were aligned using BWA, compatible
with all tested tools. We looked in particular at the
total number of reads mapped to the correct genome
and having MAPQ score > 0. As reported in Table 4,
the ICRG and Disambiguate showed very comparable
performances while the ICRG slightly outperformed
Xenome, mapping 0.6% more reads to the human
genome in the 100% human DNA samples and 2%
more reads to the mouse genome in the 100% mouse
DNA samples.
We also compared the CPU time required in an align-
ment pipeline that included either the ICRG, Disambigu-
ate or Xenome. This was tested in the 90% human and
10% mouse DNA samples since they best approximate a
real scenario. The three alignment pipelines are de-
scribed in Additional file 3. The use of Xenome pipeline
required 3–8% more CPU time than the ICRG and the
use of Disambiguate required 35–42% more CPU time
than the ICRG (Table 5).
Table 3 Alignment of RNA-seq data from the human and mouse universal reference RNA
Sample Replicate HGR ICRG
Alignment
efficiency (%)
Alignment
efficiency (%)
Reads mapped to the human
genome (%)
Reads mapped to the mouse
genome (%)
Human universal
reference RNA
a 79.22 79.29 99.82 0.18
Human universal
reference RNA
b 78.92 78.92 99.83 0.17
Human universal
reference RNA
c 78.99 78.99 99.84 0.16
Mouse universal
reference RNA
a 5.16 5.16 1.08 98.92
Mouse universal
reference RNA
b 5.10 5.10 1.08 98.92
Mouse universal
reference RNA
c 5.18 5.18 1.23 98.77
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An alignment pipeline using STAR and either the
ICRG, Disambiguate or Xenome was applied to the
HRR and MRR RNA-seq samples. As before, we fo-
cused on the total number of reads that each method
was able to align to the correct genome. Also in
RNA-seq data the ICRG and Disambiguate showed
equivalent performances while the ICRG mapped to
the correct genome an average of 4% more reads than
Xenome (Table 4).
Overall, the comparison with existing methods to dis-
criminate reads from two different species highlighted
that our approach achieved the same performance as
Disambiguate but was significantly faster and outper-
formed Xenome in terms of accuracy.
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Discussion
The use of PDTXs as preclinical models is growing
exponentially because they better resemble clinical
tumours compared with cell lines. They are becom-
ing the model of choice to study tumour progression
and evolution, heterogeneity and pharmacogenomics
[2, 13]. At the same time, sequencing based technol-
ogy has become the standard for cancer molecular
characterization at the genomic, transcriptomic and
epigenomic levels [14–16]. As previously suggested
[11, 17], we show that standard approaches for HTS
data analysis based on the alignment of raw data to
the human genome can significantly compromise re-
sults and data interpretation. The use of a combined
reference genome has been informally suggested in
the open source community, but we demonstrate
here that the alignment to the ICRG is a simple and
effective strategy to distinguish between human and
mouse reads in PDTX samples, preventing the iden-
tification of hundreds of false positive mutations in
WES data and enabling the study of transcriptomes
and methylomes of both human cancer cells and
mouse stroma.
For WES data, we developed a model able to predict the
percentage of human/mouse DNA content in independ-
ent samples. We applied an earlier version of this model
to a cohort of breast cancer PDTXs where the average
mouse stroma content was 15% [2]. Such amount of
mouse stroma is enough to generate hundreds of false
positive mutations if the human reference genome is used
for alignment. After alignment to the ICRG, some PDTX
specific mutations (i.e. present in the PDTX but not in the
matched clinical tumour) were still detected. Importantly,
we excluded that these were caused by misaligned mouse
reads. PDTX specific mutations have several explanations:
spatial heterogeneity in the donor tumour, clonal selec-
tion/evolution upon engraftment [1, 2], coverage discrep-
ancies between the human tumour sample and the PDTX,
or false positive calls.
One of the solutions adopted in previous studies to
limit the high false positive rate caused by misaligned
mouse reads, was to obtain Whole Genome Sequencing
data for the host mouse and mask all SNVs called after
mapping the data against the human genome [1]. Al-
though the method is valid, extra sequencing data need
to be obtained and extra analyses need to be run. More-
over, the presence of masked regions (>2 × 106 SNVs)
will increase the false negative rate.
The impact of mouse reads in RNA-seq data seems to be
significantly smaller, however we still suggest aligning the
data to the ICRG to avoid any bias. Moreover, this ap-
proach enables an in silico dissection of the tumour (hu-
man) and microenvironment (mouse) expression profiles.
Obviously, the amount of genes that can be quantified in
the mouse compartment depends on both the amount of
Table 4 Comparison of the number of reads assigned to the human and mouse genome using the ICRG, Disambiguate or Xenome
ICRG Disambiguate Xenome
Data
type
%
human
%
mouse
Replicate Reads mapped
as human
Reads mapped
as mouse
Reads mapped
as human
Reads mapped
as mouse
Ambiguous
reads
Reads mapped
as human
Reads mapped
as mouse
WES
100 0 a 58,106,275 14,895 58,109,701 11,301 110,603 57,764,467 10,471
100 0 b 39,554,955 12,132 39,557,693 9281 97,294 39,298,032 8847
100 0 c 25,372,704 7216 25,374,460 5414 67,498 25,204,254 5359
0 100 a 41,454 32,542,045 73,117 32,497,314 364,417 41,821 31,900,526
0 100 b 39,132 31,217,211 70,693 31,173,450 366,702 39,238 30,586,007
0 100 c 49,731 44,526,608 90,060 44,470,789 455,206 49,964 43,674,812
RNA-seq
100 0 a 53,106,950 212,696 53,021,136 242,026 181,712 50,992,384 86,370
100 0 b 56,450,410 232,876 56,364,238 260,810 212,462 54,219,538 84,236
100 0 c 46,946,248 206,112 46,856,870 220,970 199,938 45,137,450 64,950
0 100 a 1,510,196 39,721,816 1,353,926 39,543,932 428,688 875,920 38,259,766
0 100 b 1,240,462 38,081,386 1,127,872 37,942,438 342,720 737,946 36,710,860
0 100 c 1,611,790 44,442,932 1,457,070 44,267,370 446,048 956,948 42,837,414
values in italic indicate the number of reads mapped to the correct genome
Table 5 Comparison of the CPU time required by a WES
alignment pipeline including either the ICRG, Disambiguate
or Xenome
CPU Time (s)
%human %mouse Replicate ICRG Disambiguate Xenome
90 10 a 20,154 28,743 20,905
90 10 b 20,614 28,034 22,279
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stromal infiltration (biological variable that we probably
want to capture) and the sequencing depth coverage (tech-
nical variable that we want to minimise). We therefore rec-
ommend that a higher and uniform number of reads is
obtained in PDTX RNA-seq experiments. Using a sequen-
cing depth of 21 million reads and with an average mouse
read percentage of 8.5%, we found more than 4000 mouse
genes with FPKM> 1 in at least 50% of the PDTX samples.
Unsupervised analysis of these expression profiles grouped
together different passages from the same model, suggest-
ing that each PDTX model induces specific transcriptomic
changes in the mouse microenvironment that can be ex-
plored using the ICRG approach. Our RNA-seq libraries
were sequenced using the HiSeq 4000 Illumina instrument
that has been reported to be affected by ‘index hopping’,
consisting in around 1% of the reads being assigned to the
wrong barcode (i.e. sample) [18]. Although this is unlikely
to have a tangible impact in our experimental setting, some
of the reads aligned to the wrong genome could be ex-
plained by this phenomenon.
It was reassuring to observe that ICRG alignment per-
formed well with RRBS data. In this data type, the bisul-
phite treatment of samples will convert methylated
cytosine bases to thymine and then for downstream ana-
lysis all cytosine bases are converted in silico to thymine
for alignment purposes (three letter aligners) [19], redu-
cing read complexity and, consequently, making multiple
mapping or misalignment more likely. Although, similarly
to RNA-seq data, the use of the ICRG for alignment is not
strictly required, we would still recommend it since it en-
ables the methylome profiling of the mouse stroma.
An important aspect of this work is that the experi-
ments generated using controlled dilutions represent a
relevant benchmark dataset for further investigations.
All sequencing data generated in this study are available
through the European Genome-Phenome Archive (EGA,
https://ega-archive.org/) under accession number
EGAD00001003800.
Importantly, we compared our method with previously
reported methods, namely Disambiguate [12] and
Xenome [11]. Our method was able to recover a higher
number of reads mapped to the correct genome than
Xenome, while showing a comparable performance with
Disambiguate. However, an alignment pipeline using the
latter required around 40% more time to complete, a
significant difference for what is the most time-
consuming step in the analysis of HTS data. Moreover,
the implementation of an ICRG-based pipeline is com-
patible with any alignment software and does not re-
quire any extra software to be installed and
incorporated, but only the ‘one-off ’ generation of aligner
indices. To facilitate a smooth implementation of our
method, all the relevant code is available at https://
github.com/cclab-brca/ICRG.
Conclusions
In conclusion, we present here a straightforward strat-
egy, based on the use of ICRG for read alignment, which
is able to handle the presence of mouse reads in PDTX
sequencing data. We demonstrate that this approach is
efficient in removing mouse reads before performing
somatic mutation calling and that it allows estimation of
the human/mouse DNA content in the xenograft sam-
ple. In addition, the use of the ICRG enables human
tumour and mouse stroma specific analysis of transcrip-
tome and methylome profiles. In a direct comparison
with previously reported methods we observed similar
or higher performances in terms of accuracy and a sig-
nificantly reduced computational time.
Methods
Sample description
We used a surgical tumour sample and mouse mam-
mary fat pad as a source of pure human and mouse tis-
sue. In this study, we also included 5 breast cancer cases
and their matched PDTXs (Additional file 1) that are
part of our previously reported biobank [2]. Signed con-
sent was obtained from the patients whose tumour sam-
ples were used in this study and all research was
conducted with the appropriate approval by the National
Research Ethics Service [Cambridgeshire 2 REC refer-
ence number: 08/H0308/178]. Mice were bought from
Charles River®. Animals were euthanised by cervical dis-
location and death confirmed by a secondary method ac-
cording to Schedule 1 of the Scientific Procedure Act
(1986). Tumour tissue was removed in aseptic condi-
tions and all animal experiments were conducted in
compliance with the rigorous Home Office framework
of regulations (Project License 707,679).
Pure human and mouse reference RNAs were purchased:
Universal Human Reference RNA (HRR, Agilent Technolo-
gies Inc., USA, 740,000); and Universal Mouse Reference
RNA (MRR, Agilent Technologies Inc., USA, 740,100).
Nucleic acid purification
DNA was extracted from all samples using the Qiagen
Blood and Tissue kit (Cat ID, 69,504) as per manufac-
turer’s instructions. To generate a human-mouse DNA
dilution series, human and mouse pure DNA concentra-
tion was normalised and then mixed in predefined pro-
portions volumetrically.
RNA was extracted from all samples using the Qiagen
miRNeasy kit (Cat ID, 217,004) as per manufacturer’s
instructions.
Reference genomes for read alignment
Two reference genomes were used in our study. The
first was the standard Human Reference Genome (hg19/
GRCh37 decoy) hereafter called HRG. The second was
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the ICRG, generated by combining the aforementioned
HRG with the mouse reference genome (mm10). Mouse
chromosomes were renamed as “m.chr” and then the
two fasta files (human and mouse) were concatenated.
The concatenated fasta file was then indexed using the
appropriate tool provided by each aligner.
Whole exome sequencing
WES libraries were prepared using Nextera Rapid Cap-
ture Exome (Illumina Inc., USA) following manufac-
turer’s instructions [2]. Sequencing was performed using
75 bp paired-end reads for the human/mouse dilution
series and 125 bp paired-end reads for human and
PDTX samples. Demultiplexing was performed using
bcl2fastq2 v.2.17 software allowing 0 mismatches. Se-
quencing quality of raw fastq files was assessed using
FastQC (v 0.11.5, http://www.bioinformatics.babraham.a-
c.uk/projects/fastqc).
Raw data were processed according to the ITC ap-
proach described in [20]. Briefly, alignment was per-
formed using BWA-MEM (v 0.7.12) and Novoalign (v
3.02) followed by mutation calling with Mutect2 and
Strelka. Only the intersection of mutations called by the
same caller after different alignment were retained.
Then, mutations called by the two callers were merged
to generate the final set of identified somatic mutations
(SNVs and Indels). Alignment efficiency (i.e. the percent-
age of reads that aligned to the reference sequence) and
statistics were derived from Novoalign-aligned bam files
using Picard Tools (v 1.140) or custom scripts (https://
github.com/cclab-brca/ICRG). The same pipeline was
applied using either the HRG or the ICRG in the align-
ment step. For each PDTX-clinical tumour pair, the vari-
ant allele frequencies (VAFs) of the mutations called in
at least one sample were re-computed in both samples
using GATK HaplotypeCaller (v 3.5). If the VAF was
>1% in both samples the mutation was defined as com-
mon, otherwise it was defined as either tumour specific
or PDTX specific.
In WES data from the human-mouse DNA dilution
series aligned using the ICRG, we used custom bash
code to compute the percentage of reads mapped to the
human genome. Using the R package mgcv [21] these
values and the known percentage of human DNA in the
sample were used to derive a calibration curve applying
penalized regression splines with a basis dimension of 3.
RNA-sequencing
Libraries for Illumina sequencing were prepared using
TruSeq Stranded mRNA HT kit (Cat ID, RS-122-2103,
Illumina). 500 ng of total RNA with RNA Integrity
Numbers (RINs) above 8 was used for library prepar-
ation. Samples were processed following manufacturer’s
HS (High-Sample) instructions (part# 15031048 Rev. E,
Illumina) with 12 cycles of PCR used at the Enrichment
of DNA Fragments step. All libraries were quantified
using KAPA Library Quantification Kit Illumina ROX
Low (Cat ID, KK4873, KAPA Biosystems) and normal-
ised. Libraries were pooled in equal volumes and pools
were used for clustering on HiSeq4000 sequencing flow
cell following manufacturer’s instructions. Sequencing
was performed using 150 bp paired-end run type for
dual-indexed libraries.
Demultiplexing was performed using bcl2fastq2 v.2.17
software allowing 0 mismatches. Sequencing quality of
raw fastq files was assessed using FastQC (v 0.11.5,
http://www.bioinformatics.babraham.ac.uk/projects/
fastqc) and alignment to HRG or ICRG was performed
using STAR v2.5.2 in two-pass mode for splice-aware
read alignment [22]. The resulting BAM file was then
assessed using RNASeQC (v1.1.8) [23].
Counting of reads aligned over exonic features for the
purpose of gene expression quantification was per-
formed using the htseq-count script in the HTSeq pack-
age (v 0.6.1) in ‘Union’ overlap resolution mode [24].
The Gene Transfer Format (GTF) file used for the pur-
poses of counting was a merged Homo sapiens and Mus
musculus GTF file, both obtained from Ensembl (http://
www.ensembl.org), and modified to ensure chromo-
somal compatibility with the ICRG. The resulting counts
for all samples were then collated and FPKM calcula-
tions per gene per sample were performed using the
rpkm() function in the edgeR R package [25].
RRBS
DNA was quantified using Quant-iT High Sensitivity
dsDNA Assay (Thermo Fisher, USA) and 200 ng was
used as input for RRBS library preparation. DNA was
subjected to an optimised protocol [26] and pooled prior
to bisulphite conversion using Zymo Research EZ DNA
Methylation gold kit (Cat ID, D5006). Pooled bisulphite
converted samples were amplified with 15 cycles of PCR
and purified twice with SPRI beads (Agencourt AMPure
XP, Beckman Coulter, Cat ID A63880) for size selection,
using 2X then 1.5X volume of the elute. Libraries were
assessed for concentration and quality respectively using
qPCR (KAPA Biosystems, KK4873) and DNA High sen-
sitivity chip on Bioanalyser 2100 (Agilent Technologies
Inc., USA). RRBS sequencing was performed using
125 bp paired-end reads. Demultiplexing was performed
using bcl2fastq2 v.2.17 software allowing 0 mismatches.
Sequencing quality of raw fastq files was assessed using
FastQC (v 0.11.5, http://www.bioinformatics.babraham.a-
c.uk/projects/fastqc). Bismark (version 0.13.1) was used
for read alignment and to derive alignment stats. Only
CpGs with at least 5× coverage were selected for subse-
quent analysis. The pipeline was run twice, using HRG
and ICRG, respectively.
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Comparison with other methods
In the comparison analysis, alignment was performed using
BWA-MEM (v 0.7.12) for WES data and STAR v2.5.2 for
RNA-seq data. Our approach was compared to Disambigu-
ate [12] (C++ version downloaded from https://github.-
com/AstraZeneca-NGS/disambiguate) and Xenome [11]
included in the Gossamer bioinformatics suite (https://
github.com/data61/gossamer). The number of reads map-
ping to each genome was computed using samtools and
the grep function as detailed in the code available at
https://github.com/cclab-brca/ICRG. For the 90% human
and 10% mouse DNA samples, the CPU time was extracted
from the pipeline log file and a pipeline description for each
method is reported in Additional file 2.
Other analyses
Bam files were visualized using IGV (http://software.b-
roadinstitute.org/software/igv/). Processed data mining
and graphical representation of the results were per-
formed using R/Bioconductor (v 3.2.2).
Additional files
Additional file 1: Molecular data generated - Table detailing which
molecular data (WES, RNA-seq or RRBS) were generated for each sample
included in the study. (XLSX 39 kb)
Additional file 2: WES alignment pipelines including either the ICRG,
Disambiguate or Xenome - Schematic representation of the WES
alignment pipelines developed to compare the ICRG method with
Disambiguate and Xenome. (PPTX 41 kb)
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